Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, October 25, 2026

Back to today

From X

@kevin__mak 2 clicks

Kevin Mak on X

$CMPS Great article this weekend in Politico about psychedelics. There's overwhelming alignment across the government to moving these treatments forward. Given this, I really can't see COMP360 getting ensnared in the approval process, or worse, through reimbursement/REMS bureaucracy once commercialized. At current prices, I believe the market is treating CMPS as a "risky proposition" because historically, that was very true. I think that regime has changed dramatically in the last 12 months. Spend some time talking to an LLM about COMP360 vs Spravato (>$2B/year in sales). Which would you rather take? But even more importantly, Spravato has <5% market share of Treatment Resistant Depression, the other ~95% of patients are generally seeking options. Disclosure: Creek Drive and its affiliated funds holds a long position in CMPS. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information. --- The VA has led the push in Washington to advance access to psychedelic therapy. It’s involved in 20 psychedelic clinical trials and was one of the first major health care systems to roll out Spravato, an FDA-approved treatment for depression using esketamine, a chemical component found in ketamine. Ketamine — an anesthetic frequently referred to as a psychedelic due to its psychoactive effects — is currently the only psychedelic-like drug approved for medical use. Trump administration officials say they hope more will be approved soon. “We want to see the drug approved if it’s safe and effective, and the reason why is because there’s a mental health crisis,” Matt Zorn, deputy general counsel at the Health and Human Services Department, told POLITICO.
@aleabitoreddit 5 clicks

Serenity on X

Just another $40B going into the "AI Infra" Bubble... Elon stated this $SPCX financing would primarily fund $NVDA GPU procurement H1 2027. Which indirectly increases demand for memory, networking, etc needed. In some other notes, VPEC today in UDN: "InP substrates is seriously in short supply" in regards to suppliers like $AXTI. - Morgan Stanley believes that InP substrates, EML and CW lasers will be the primary bottlenecks - VPEC emphasized that whoever can secure more raw material supply in the future will have greater pricing power and influence in the market. Very true about supply procurement... both upstream materials like epiwafers/substrates to ultimately compute. We're in a volatile period where all your largest companies in the world are fighting over control of the future of AI infrastructure. Any slowdown seems unlikely.
@aleabitoreddit 3 clicks

Serenity on X

Not actively. I've been pointing out issues with Neocloud/Colo financing since 2025 from $SLNH to $CRWV debt interest. And maintain my opinion only a few neoclouds would survive in a few years, given they build enough of a moat to differentiate themselves against hyperscalers. So I don't think Elon's comments are completely wrong about Neoclouds, but there's nuances. One example was $NBIS SOFR + 2.75% $3.5B facility with Citibank, which actually has better rates than GPU financing from $2T+ companies. So kinda hard to say neocloud financing has "entirely shut off" since this Citibank facility was announced 3D ago I'm not arguing the merits of Elon's claims here. There's some truth to them, even if they're framed in extremes. I'm happy to hear his opinion on the direction of the industry... but if they're mainly amplifying concerns about competitor downfall (which benefits $SPCX + $TSLA) There's some cause for concern about how healthy that is to the town square dynamic Elon originally envisioned with X.
@calvinblissett 4 clicks

Calvin Blissett on X

$MP. You guys know me I am CHEAP, negative enterprise value, double digit dividend yields cheap. The theme behind $MP looks very secular, I saw Ross Perot call what they have in California the “Saudi’s Arabia” of magnets. Analysts price targets are virtually all 100% above today’s price. The selloff is not justified based on the underlying commodity price (aka fundamentals) is my takeaway from some reading. I also spoke with someone who worked at BofA this summer and per him “on a call with a senator the senator was essentially just repeating buy $MP and the moderator said shut up and stop”. May someone with a bigger brain then me give their thoughts
@calvinblissett 1 click

Calvin Blissett on X

$MP. You guys know me I am CHEAP, negative enterprise value, double digit dividend yields cheap. The theme behind $MP looks very secular, I saw Ross Perot call what they have in California the “Saudi’s Arabia” of magnets. Analysts price targets are virtually all 100% above today’s price. The selloff is not justified based on the underlying commodity price (aka fundamentals) is my takeaway from some reading. May someone with a bigger brain then me give their thoughts
@RPavuluri 6 clicks

Rohan Pavuluri on X

Always amazed when I learn about a new public company for the first time. Especially one that did YC and is based in SF/NYC. @BillionToOneInc is a $5B+ public company ($BLLN) that I never heard of before today. Despite it being YC S17 and the fact that I did YC myself a couple batches afterwards, I had no clue it existed. As far as I can tell, it's @ycombinator's biggest bio success story too. Checked the X account and it has 1,302 followers. Have never seen on a podcast, a wsj article, on the timeline, etc. but yet a monster bio company making very real revenue! Goes to show that there are likely multiple companies founded in last 10 years (not just the sleepy under the radar midwest ones from decades ago) still based in hot areas (BillionToOne is in Menlo Park) that still don't show up on the "timeline" and are even public (BillionToOne IPOed last year) that fly very under the radar...looks like the buzz makes no difference to its success!

Investor Letters

All letters

MYR Group q3’26 Earnings Preview

MYR Group’s Q3 2026 preview cites data-center and power transmission demand, with long-term service agreements supporting margin growth and…

MYRG $4B
Monte Independent Investment Research 5 clicks

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

MOS $5.5B
Latticework by MOI Global 33 clicks
RXO · short

Rxo INC

RXO, a top-five U.S. freight broker, carries roughly 5x LTM EBITDA leverage and undisclosed off-balance-sheet liabilities after its 2022…

RXO $4.7B
Value Investors Club

Build-A-Bear: A Narrower Path

Build-A-Bear's push into prestuffed toys and broader retail distribution tests brand stretchability, but recent results warrant caution.

BBW $292M
TSOH Investment Research 18 clicks

Twenty Years in the Dark

Tower Properties, $TPRP, went dark after a 2006 squeeze-out cut holders below 300, leaving a Kemper-controlled apartment and office…

TPRP $128M
Orphan REITs 5 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 62 of 253

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.